JP2021522793A5 - - Google Patents

Info

Publication number
JP2021522793A5
JP2021522793A5 JP2020561726A JP2020561726A JP2021522793A5 JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5 JP 2020561726 A JP2020561726 A JP 2020561726A JP 2020561726 A JP2020561726 A JP 2020561726A JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
acid sequence
item
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030469 external-priority patent/WO2019213442A1/en
Publication of JP2021522793A publication Critical patent/JP2021522793A/ja
Publication of JP2021522793A5 publication Critical patent/JP2021522793A5/ja
Pending legal-status Critical Current

Links

JP2020561726A 2018-05-03 2019-05-02 TGFβスーパーファミリーリガンドの多特異性バインダーおよびその使用 Pending JP2021522793A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666547P 2018-05-03 2018-05-03
US62/666,547 2018-05-03
US201862779998P 2018-12-14 2018-12-14
US62/779,998 2018-12-14
PCT/US2019/030469 WO2019213442A1 (en) 2018-05-03 2019-05-02 MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2021522793A JP2021522793A (ja) 2021-09-02
JP2021522793A5 true JP2021522793A5 (cg-RX-API-DMAC7.html) 2022-05-13

Family

ID=68386158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561726A Pending JP2021522793A (ja) 2018-05-03 2019-05-02 TGFβスーパーファミリーリガンドの多特異性バインダーおよびその使用

Country Status (6)

Country Link
US (2) US12103959B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788066A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021522793A (cg-RX-API-DMAC7.html)
AU (1) AU2019262139A1 (cg-RX-API-DMAC7.html)
CA (1) CA3099527A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019213442A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119136A1 (en) * 2019-12-10 2021-06-17 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
CA3196443A1 (en) * 2020-11-04 2022-05-12 Hq Han Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
HRP20210977T1 (hr) * 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
JP6631865B2 (ja) 2014-08-11 2020-01-15 日本化薬株式会社 TGFβ阻害機能を持つキメラタンパク質
CN113683708A (zh) * 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
AU2017293778B2 (en) 2016-07-07 2022-03-24 Acceleron Pharma Inc. TGF-beta superfamily heteromultimers and uses thereof
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3522912A4 (en) * 2016-10-05 2020-10-14 Acceleron Pharma Inc. HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
CN206301918U (zh) * 2016-12-23 2017-07-04 深圳国人通信股份有限公司 一种介质移相器
WO2018213446A1 (en) 2017-05-16 2018-11-22 Cornell University Graphenic fibers, yarns, composites, and methods of making the same
EP3788067A4 (en) 2018-05-03 2022-01-19 Acceleron Pharma Inc. NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
US20220089683A1 (en) 2018-06-15 2022-03-24 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof

Similar Documents

Publication Publication Date Title
JP2021522795A5 (cg-RX-API-DMAC7.html)
US11918647B2 (en) TfR selective binding compounds and related methods
CN104245735B (zh) Cx3cr1结合多肽
JP6809789B2 (ja) 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2022523524A5 (cg-RX-API-DMAC7.html)
JP2021175391A5 (cg-RX-API-DMAC7.html)
US20220177597A1 (en) Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries
US20230348565A1 (en) Methods of using activin receptor type ii variants
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
EA032727B1 (ru) Мутантный резистентный к протеолизу полипептид fgf21 и его применение
CN106687478A (zh) 新的抗人Tie‑2抗体
JP2023522799A5 (cg-RX-API-DMAC7.html)
US20180280474A1 (en) Treatment of bile acid disorders
JP2021513366A (ja) 抗pd−1/抗her2天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法
JP2020500511A5 (cg-RX-API-DMAC7.html)
JP2022540918A5 (cg-RX-API-DMAC7.html)
CN112839681A (zh) 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
JP2025527160A (ja) 多重特異性抗体およびその使用
JP2025116068A (ja) 腎臓活性融合タンパク質及びそれを使用する治療方法
AU2022316521B2 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
JP2025524899A (ja) メソテリン結合タンパク質及びその使用
CN117295758A (zh) 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白
JP2024537397A5 (cg-RX-API-DMAC7.html)
WO2026037338A1 (zh) 一种阻断baff、april作用其受体的融合蛋白
JP2024537234A5 (cg-RX-API-DMAC7.html)